Physician profile
Robert E Sheir
NPI 1477517357
$1,790.19
in general payments reported to CMS, 2019-2025
16 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $193 · 2021: $368 · 2022: $453 · 2023: $50.00 · 2024: $54.81 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $271.12 | 2019-2024 | |
| Optos, INC. | $230.55 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $159.53 | 2022 | |
| Sight Sciences, INC. | $147.42 | 2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $144.23 | 2022-2025 | |
| Alcon Vision LLC | $130.92 | 2019 | |
| Genzyme Corporation | $121.99 | 2019 | |
| Eyevance Pharmaceuticals LLC | $116.88 | 2021 | |
| Maculogix, INC. | $114.61 | 2020 | |
| Glaukos Corporation | $93.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $92.01 | 2019 | |
| Oyster Point Pharma, INC. | $50.00 | 2023 | Tyrvaya |
| Visionix USA, INC | $46.88 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.54 | 2021 | |
| Coopervision INC. | $21.15 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sheir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.